Marc Hedrick's guest appearances

Marc Hedrick

Empowered Patient Podcast

Welcome to the Arena

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Millions of Americans with medical conditions spend years waiting for breakthrough treatments. Today's guest is making extraordinary advances in cancer treatment to significantly improve outcomes.Today we're sitting down with Dr. Marc Hedrick, President and CEO at Plus Therapeutics whose stock trades under the symbol PSTV. Previously, Dr. Hedrick served in a number of executive leadership roles, including President, CEO and Director of Cytori Therapeutics, and President and CEO of STEM Source. He's a trained general vascular and plastic surgeon, and former Associate Professor of Surgery and Pediatrics at UCLA. He also served as co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick received his MD from University of Texas Southwestern Medical School Dallas, and an MBA from the Anderson School at UCLA in 2005. We talked about his company's incredible new technology that is revolutionizing how some cancers can be treated. Highlights: Marc describes his background, and path to the medical field (2:52) How Plus Therapeutics approaches their work to change outcomes for debilitating diseases (3:34) How Plus Therapeutics targeted treatment differs from traditional radiotherapy (5:19) Marc breaks down how the company chooses what types of cancer to develop treatments for (6:11) How Plus Therapeutics is driving innovation (7:39) What treatments their distinctive drugs can be used for and how they work (9:44) Plus Therapeutics partnerships, and what the company looks for in a partner (12:16) How the company managed challenges through the COVID-19 pandemic (13:47) Competition in the CNS space, and the challenges Plus Therapeutics faced introducing a new treatment (15:18) Funding, and the company's unique capitalization strategy (16:33) The competitive landscape (18:32) Plus Therapeutics leadership team, and value of culture (20:16) Locational benefits, and the entrepreneurial ecosystem in Texas (21:42) Marc's predictions on the future of the radiotherapy industry (22:59) What investors might not understand about this company (24:42) Links:ICR TwitterICR LinkedInICR WebsiteMarc Hedrick on LinkedInPlus Therapeutics on LinkedInPlus Therapeutics WebsiteFeedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.

Millions of Americans with medical conditions spend years waiting for breakthrough treatments. Today's guest is making extraordinary advances in cancer treatment to significantly improve outcomes.Today we're sitting down with Dr. Marc Hedrick, President and CEO at Plus Therapeutics whose stock trades under the symbol PSTV. Previously, Dr. Hedrick served in a number of executive leadership roles, including President, CEO and Director of Cytori Therapeutics, and President and CEO of STEM Source. He's a trained general vascular and plastic surgeon, and former Associate Professor of Surgery and Pediatrics at UCLA. He also served as co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick received his MD from University of Texas Southwestern Medical School Dallas, and an MBA from the Anderson School at UCLA in 2005. We talked about his company's incredible new technology that is revolutionizing how some cancers can be treated. Highlights:<ul> <li>Marc describes his background, and path to the medical field (2:52)</li> <li>How Plus Therapeutics approaches their work to change outcomes for debilitating diseases (3:34)</li> <li>How Plus Therapeutics targeted treatment differs from traditional radiotherapy (5:19)</li> <li>Marc breaks down how the company chooses what types of cancer to develop treatments for (6:11)</li> <li>How Plus Therapeutics is driving innovation (7:39)</li> <li>What treatments their distinctive drugs can be used for and how they work (9:44)</li> <li>Plus Therapeutics partnerships, and what the company looks for in a partner (12:16)</li> <li>How the company managed challenges through the COVID-19 pandemic (13:47)</li> <li>Competition in the CNS space, and the challenges Plus Therapeutics faced introducing a new treatment (15:18)</li> <li>Funding, and the company's unique capitalization strategy (16:33)</li> <li>The competitive landscape (18:32)</li> <li>Plus Therapeutics leadership team, and value of culture (20:16)</li> <li>Locational benefits, and the entrepreneurial ecosystem in Texas (21:42)</li> <li>Marc's predictions on the future of the radiotherapy industry (22:59)</li> <li>What investors might not understand about this company (24:42)</li> </ul>Links:<a href="https://twitter.com/icrpr?lang=en" rel="nofollow" target="_blank">ICR Twitter</a><a href="https://www.linkedin.com/company/icr/" rel="nofollow" target="_blank">ICR LinkedIn</a><a href="http://icrinc.com" rel="nofollow" target="_blank">ICR Website</a><a href="https://www.linkedin.com/in/marc-hedrick-22a06232/" rel="nofollow" target="_blank">Marc Hedrick on LinkedIn</a><a href="https://www.linkedin.com/company/plustherapeutics/" rel="nofollow" target="_blank">Plus Therapeutics on LinkedIn</a><a href="https://plustherapeutics.com/" rel="nofollow" target="_blank">Plus Therapeutics Website</a>Feedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, <a href="mailto:marion@lowerstreet.co">marion@lowerstreet.co</a>.

Dr. Marc Hedrick, President & CEO, Plus Therapeutics - The Plus Side: Making groundbreaking developments in cancer research

Dr. Marc Hedrick, President and CEO, PLUS Therapeutics describes the challenges of fighting brain cancers like glioblastoma. The PLUS lead investigational asset Rhenium NanoLiposome (RNL) delivers radiation directly to the tumor using a method called Convection Enhanced Delivery.  This approach allows the neurosurgeon to put catheters directly into the brain by using stereotactic brain biopsy, imaging and software driven planning bypassing the normal structures and delivering 20 or more times the amount of radiation than can be delivered by external beam radiation. @PLUStxinc #braincancer #braintumor #GBM #Glioblastoma #RNL #Oncology #RareDisease #Neurosurgery #Nanotechnology #radiotherapy #pharmaceuticals #NIH #FDA #OrphanDrug #FastTrack $PSTV PLUSTherapeutics.com Download the transcript here

Dr. Marc Hedrick, President and CEO, PLUS Therapeutics describes the challenges of fighting brain cancers like glioblastoma. The PLUS lead investigational asset Rhenium NanoLiposome (RNL) delivers radiation directly to the tumor using a method called Convection Enhanced Delivery.  This approach allows the neurosurgeon to put catheters directly into the brain by using stereotactic brain biopsy, imaging and software driven planning bypassing the normal structures and delivering 20 or more times the amount of radiation than can be delivered by external beam radiation. @PLUStxinc #braincancer #braintumor #GBM #Glioblastoma #RNL #Oncology #RareDisease #Neurosurgery #Nanotechnology #radiotherapy #pharmaceuticals #NIH #FDA #OrphanDrug #FastTrack $PSTV <a href="http://PLUSTherapeutics.com" rel="noopener nofollow" target="_blank">PLUSTherapeutics.com</a> <a href="http://empoweredpatientradio.com/infusing-rhenium-nanoliposomes-into-glioblastoma-showing-high-efficacy-eradicating-these-brain-tumors-with-dr-marc-hedrick-plus-therapeutics-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Infusing Rhenium NanoLiposomes into Glioblastoma  Showing High Efficacy Eradicating These Brain Tumors with Dr. Marc Hedrick PLUS Therapeutics